Wegovy for Teens: FDA Approval & STEP TEENS Results

The FDA approved Wegovy (semaglutide) for adolescents aged 12 and older with obesity in December 2022 — and since then, the conversation around GLP-1 medications for teenagers has expanded rapidly. Here’s what parents and teens need to know about the evidence, safety, and access.

Is Wegovy Approved for Teens?

Yes. In December 2022, the FDA approved Wegovy (semaglutide 2.4mg weekly) for chronic weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). This makes Wegovy the first GLP-1 medication FDA-approved for adolescents. Ozempic (semaglutide for type 2 diabetes) is approved for children 10 and older with T2D.

The Teen Trial: STEP TEENS Results

The STEP TEENS trial enrolled 201 adolescents aged 12–17 with obesity and randomized them to semaglutide 2.4mg weekly vs placebo for 68 weeks. Results:

Outcome	Semaglutide	Placebo
Average BMI change	-16.1%	+0.6%
Average body weight change	-14.7 lbs more than placebo	—
Achieved ≥5% weight loss	75%	19%
Achieved ≥10% weight loss	62%	8%
Achieved ≥20% weight loss	34%	2%
Cardiometabolic improvements	Significant (blood pressure, lipids, A1C)	Minimal

A 16.1% reduction in BMI is highly clinically significant. For context, lifestyle interventions alone typically produce 1–5% BMI reduction in adolescents.

Safety Profile in Adolescents

The safety profile in teens mirrored what’s seen in adults. GI side effects (nausea, vomiting, diarrhea) were the most common adverse events — about 62% of semaglutide-treated adolescents vs 42% of placebo group reported GI events. Discontinuation rates due to side effects were around 4–5%. No new safety signals emerged compared to the adult trials, and the thyroid and pancreatitis warnings that apply to adults also apply to adolescents.

Concerns and Considerations for Teen Use

Consideration	Details
Growth and development	Adequate protein and nutrient intake critical; reduced appetite may affect growth
Bone density	Weight loss can affect bone density in adolescents; calcium/Vitamin D important
Eating disorder risk	Careful screening recommended; medication should not be used with active ED
Mental health monitoring	Body image issues in teens warrant ongoing mental health support
Long-term use in minors	Data beyond 68 weeks limited; ongoing monitoring recommended
Weight regain after stopping	Same rebound risk as adults; obesity management is ongoing

Who Qualifies for Wegovy as a Teen?

FDA criteria for adolescent use: age 12 or older, BMI at or above the 95th percentile for age and sex (classified as obesity), and the medication must be used as an adjunct to reduced-calorie diet and increased physical activity. Most pediatric obesity specialists also recommend a trial of intensive behavioral therapy before or alongside pharmacotherapy.

How to Access Wegovy for a Teen

The prescriber pathway for teens is typically through a pediatrician or pediatric endocrinologist with experience in adolescent obesity management. Pediatric obesity specialty clinics are a strong starting point. Some telehealth providers that specialize in adolescent care are also beginning to offer GLP-1 prescriptions for eligible teens, though this varies by state and provider.

Insurance coverage for adolescents follows similar patterns as adults — commercial plans increasingly cover Wegovy for qualifying teens, while Medicaid coverage varies significantly by state.

The Controversy: Is Medicating Teen Obesity the Right Approach?

The use of GLP-1 medications in adolescents is not without debate. Critics raise concerns about medicalizing a developmental phase, long-term effects on a developing body, potential psychological effects of rapid body weight changes, and whether adequate lifestyle support is in place. Proponents point to the serious health consequences of adolescent obesity — cardiovascular risk, T2D, orthopedic problems, mental health impacts — and argue that effective treatment should not be withheld when it’s needed.

The American Academy of Pediatrics (AAP) updated its obesity guidelines in 2023 to explicitly recommend pharmacotherapy (including GLP-1s) for adolescents with obesity alongside lifestyle treatment — a shift from previous watchful waiting approaches.

Frequently Asked Questions

Can a 13-year-old take Ozempic or Wegovy?
Wegovy is FDA-approved for ages 12 and older with obesity. Ozempic is approved for ages 10 and older with type 2 diabetes. Both require a prescription from a qualified healthcare provider who has evaluated the teen’s specific situation, health history, and appropriateness for treatment.

Does Wegovy stunt growth in teens?
There is no evidence from the STEP TEENS trial that semaglutide stunts growth. However, adequate protein and nutritional intake is critical during adolescent development, and prescribers should monitor growth parameters regularly.

How much weight can a teenager lose on Wegovy?
The STEP TEENS trial showed an average BMI reduction of 16.1% over 68 weeks, with 34% of teens achieving 20%+ body weight loss. Results vary significantly by starting weight, adherence, and lifestyle factors.

Is Wegovy covered by insurance for teens?
Coverage varies. Many commercial plans that cover Wegovy for adults will also cover it for qualifying adolescents. Medicaid coverage depends on the state. Novo Nordisk’s savings programs may apply to commercially insured teen patients.